Vioxx removed from the drug market

Vioxx is a nonsteroidal anti-inflammatory drug (NSAID) produced by Merck that was marketed as a safer alternative to other NSAID medications, such as aspirin, ibuprofen, or naproxen. Vioxx was introduced to the American public around May 1999. Furthermore, physicians typically prescribed Vioxx as an anti-inflammatory pain reliever for persons suffering from arthritis, although it also was used as an alternative or supplement to narcotic painkillers in other patients, including cancer patients.

The manufacturer, Merck, withdrew Vioxx from the American market on September 30, 2004. Studies indicate that Vioxx can cause constriction of the blood vessels and can promote blood clotting, which can lead to acute heart attack or stroke. Claims are based on information that Merck did not adequately warn users of these risks. If you, or someone you know, has suffered damage as a result of Vioxx, please call us so we may help you receive compensation.

Dr. Michael I. Lewis
936 County Line Road
Bryn Mawr, PA 19010

Degrees
DMD University of Pennsylvania 1974-1979
RPh., BS Philadelphia College of Pharmacy and Science 1974
Certificate in Nutritional Counseling 1981

Certificates and Recent Courses
3 years Pharmacology {Philadelphia College of Pharmacy and Science}
(The study of drug interactions and drug induced contra-indications that can cause serious side effects - 1976-77-78)
Balancing Body Chemistry, Bryn Mawr, PA 81-88 Fordam Page Clinic

Chromatographic Analysis of Volatile Sulfur Compounds 96

Nutritional Counseling 84-86

Applied Kinesiology Dr. George Eversol Applied Methods 83

Oral Mal Odor A Periodontal Perspective Perry R. Klokkeooli DMD 1999
Evaluation with Hallimeter Volatile Sulfur Compounds ppm. 2000
Principles of Pharmacology and Antibiotic Therapy Dr. D. Hunt; Dr. M. Newman 2001
Gingival Cysts and Neoplasm's Dr. Heddie Sedano DDS 2001
Laser Caries Detection Academy of GD 2001
Lysine Supplements in Control of Herpes Labialis Academy of GD 11/01
Bipolar Electro-surgery 2001
Periodontitis as a risk factor for Cardiovascular Disease 2001-03
Aids Vaccine Update 2001-04
Cardiac Pulmonary Resuscitation 1979-2004

I have been actively involved in research in the areas of mercury toxicity and its effects on children and adults. I have been an advocate in attempting to eliminate mercury-based fillings from being utilized in dental oral care.

I have studied the environmental effects of toxic chemicals in the environment and have a special interest in phototoxity and skin cancer. During the last 10 years I have manufactured and developed a line of non-photo protective skin care products.

A large area of concern where I have consulted is the harmful effects of drug interactions. Vasoconstriction drugs and their effect on strokes is one of the areas. Anti-inflammatory drugs such as Vioxx and other inhibitors are other active concerns of mine. Part of my consultation to the Lewis Law Firm involves weekly research of the latest FDA problem areas and warnings on new drugs and medical devices.

Ties That Bind
For years, pharmaceutical companies have courted America’s doctors with an ever-growing intensity, showering them with billions of dollars’ worth of gifts, consulting fees and trips to persuade them to prescribe their drugs. Read more...

Recent Study Results as to the Cause of Vioxx Heart Risk
Researchers believe they have found what actually caused Vioxx to boost heart risks for persons taking the drug. As we all know, the pain reliever was taken off the market in 2004 because it was linked to a high risk of heart attack and stroke. Read more...

Merck Loses Bid for New Trial in New Jersey Vioxx Case
A New Jersey judge has upheld a $13.5 million verdict against drug maker Merck & Co. in a Vioxx case. The August 7th ruling by Atlantic County Superior Court Judge Carol Higbee denied Merck’s request for a new trial or a reduction in the verdict, which included punitive damages of $9 million. Read more...

Vioxx removed from the drug market
The manufacturer, Merck, withdrew Vioxx from the American market on September 30, 2004. Studies indicate that Vioxx can cause constriction of the blood vessels and can promote blood clotting, which can lead to acute heart attack or stroke. Read more...